Navigation Links
Gevo Doesn't Infringe Butamax's '017 Patent; Gevo was First to Invent Enzyme in '017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
Date:8/8/2012

ENGLEWOOD, Colo., Aug. 8, 2012 /PRNewswire/ -- Gevo, Inc. (NASDAQ: GEVO), a leading renewable chemicals and next-generation biofuels company, said today that the latest lawsuit filed by Butamax™ Advanced Biofuels LLC (Butamax) alleging infringement by Gevo of Butamax's U.S. Patent No. 8,222,017 ('017 Patent), like the last one filed by Butamax against Gevo, will be shown to have no merit.  Gevo said it is also challenging the validity of Butamax's '017 Patent.

"We don't infringe the enzyme claimed in Butamax's patent," said Brett Lund, Executive Vice President and General Counsel of Gevo. "Gevo previously developed and patented a modified E. coli KARI enzyme, and since then, our technology has advanced well beyond this. Our industry-leading process now utilizes an enzyme that is not derived from, or in any way related, to the E. coli KARI enzyme described in the newly issued patent. We provided proof of our non-infringement to Butamax and they still sued us." 

"We also challenge the validity of the just-issued Butamax patent. We strongly believe that Gevo was the first to invent the claimed subject matter," Lund said. "Therefore, we have filed a 'Request for Interference' (Serial No. 13/271,084) with the U.S. Patent and Trademark Office to demonstrate that the technology is, in fact, a Gevo invention. Gevo's technology represents the industry standard for the optimization of the native yeast isobutanol pathway. Our commitment to innovation is what sustains this leadership position. We see this unfounded lawsuit as another attempt by Butamax to stall our significant advances in the commercialization of renewable isobutanol."

"This lawsuit is part and parcel of an ongoing effort by Butamax and its corporate parents, DuPont and British Petroleum, to divert attention from the well-established fact that much of Butamax's technology
'/>"/>

SOURCE Gevo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
5. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
6. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
9. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
10. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
11. Amgen Announces 2012 First Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Hi-Bred Biotechnology Leadership ... at Beijing Ag Summit, ... public and private sectors will help increase,farm productivity in the country ... vice president -- DuPont Crop,Genetics Research and Development, told attendees at ...
... 25 IDEXX,Laboratories, Inc. (Nasdaq: IDXX ), today ... 18% to $249.1 million from $211.2 million,for the first ... the,quarter ended March 31, 2008 were $0.43, compared to ... adjusted diluted EPS for the first,quarter grew 21% to ...
... (Nasdaq: KOSN ) will announce its first quarter ... close., The announcement of Kosan,s first quarter 2008 ... live webcast on May 1, 2008 at 1:30,p.m. Pacific ... live,call by dialing 888.680.0878 (US) or 617.213.4855 (international), access,code ...
Cached Biology Technology:DuPont Partnering with China to Increase Farm Productivity 2DuPont Partnering with China to Increase Farm Productivity 3IDEXX Laboratories Announces First Quarter Results 2IDEXX Laboratories Announces First Quarter Results 3IDEXX Laboratories Announces First Quarter Results 4IDEXX Laboratories Announces First Quarter Results 5IDEXX Laboratories Announces First Quarter Results 6IDEXX Laboratories Announces First Quarter Results 7IDEXX Laboratories Announces First Quarter Results 8IDEXX Laboratories Announces First Quarter Results 9IDEXX Laboratories Announces First Quarter Results 10IDEXX Laboratories Announces First Quarter Results 11IDEXX Laboratories Announces First Quarter Results 12IDEXX Laboratories Announces First Quarter Results 13IDEXX Laboratories Announces First Quarter Results 14IDEXX Laboratories Announces First Quarter Results 15IDEXX Laboratories Announces First Quarter Results 16IDEXX Laboratories Announces First Quarter Results 17Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results 2
(Date:4/17/2014)... and Professor Luca Razzari of the nergie Matriaux ... grants from the John R. Evans Leaders Fund ... the acquisition of state-of-the-art biotech and nanophotonics equipment. ... from the Ministre de l,Enseignement suprieur, de la ... (MESRST). These new laboratories will help us develop ...
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... the Keck School of Medicine of the University of ... estrogen, the female sex hormone, activates genes in breast-cancer ... to eventually lead to new treatments for the disease. ... of the Keck School,s Department of Biochemistry and Molecular ...
... for rare and neglected diseases that include potential treatments ... virus that affects the central nervous system of newborns, ... and a rare lung disease. The six new projects ... for Rare and Neglected Diseases (TRND) program. "These ...
... Nov. 15, 2011 The Los Angeles World Airports (LAWA), ... has awarded a contract modification to Unisys (NYSE: ... system, used to identify the 45,000 airport employees, contractors, police ... The work is an early step in LAWA,s plan ...
Cached Biology News:USC researchers discover key aspect of process that activates breast cancer genes 2NIH TRND program announces next round of drug development projects 2NIH TRND program announces next round of drug development projects 3NIH TRND program announces next round of drug development projects 4NIH TRND program announces next round of drug development projects 5Los Angeles World Airports Selects Unisys to Upgrade ID Card Reader System and Network 2Los Angeles World Airports Selects Unisys to Upgrade ID Card Reader System and Network 3